# A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer

> **NCT00381095** · PHASE4 · TERMINATED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 152 (actual)

## Conditions studied

- Bone Neoplasms
- Pain, Intractable
- Cancer

## Interventions

- **DRUG:** Pregabalin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00381095
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 152 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2021-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00381095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00381095, "A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00381095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*